Premium
Comprehensive assessment of T‐cell repertoire following autologous hematopoietic stem cell transplantation for treatment of type 1 diabetes using high‐throughput sequencing
Author(s) -
Zhang Juanjuan,
Hu Min,
Wang Bokai,
Gao Jie,
Wang Li,
Li Li,
Chen Sisi,
Cui Bin,
Gu Weiqiong,
Wang Weiqing,
Ning Guang
Publication year - 2018
Publication title -
pediatric diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.678
H-Index - 75
eISSN - 1399-5448
pISSN - 1399-543X
DOI - 10.1111/pedi.12728
Subject(s) - t cell receptor , hematopoietic stem cell transplantation , repertoire , transplantation , medicine , type 1 diabetes , t cell , immunology , oncology , diabetes mellitus , endocrinology , immune system , physics , acoustics
Objective We aimed to investigate T‐cell receptor (TCR) repertoires in type 1 diabetes (T1D) patients receiving autologous hematopoietic stem cell transplantation (AHSCT) treatment. Methods High‐throughput deep TCR beta (TCRB) chain sequencing was performed to assess millions of individual TCRs in five T1D patients receiving AHSCT treatment and another five patients receiving insulin treatment during 12 months of follow‐up. Results No significant changes in TCRB sequence reads, complementarity‐determining region 3 (CDR3) sequences, or the usage of TCRB VJ gene‐segments were observed at 12 months after AHSCT. Compared with the baseline, the usage of TCRB VJ gene‐segments at 12 months decreased in the insulin treatment group (1836.4 ± 437.7 vs 2763.6 ± 390.6, P = 0.015), and the change rates were larger than those undergoing AHSCT (−0.62 ± 0.16 vs 0.06 ± 0.45, P = 0.002). Changes in the TCR repertoire were smaller after AHSCT than those with insulin treatment ( P = 2.2*10 −32 ). TCRBV 7‐7/TCRBJ 2‐5 was depleted after AHSCT while expanded with insulin treatment. TCRBV 12‐4, TCRBV 10‐3 , TCRBV 12‐3/TCRBJ 1‐2 were expanded after AHSCT while ablated with insulin treatment. Conclusions We found that AHSCT is safe without reduction in the diversity of TCR repertoires and TCR repertoires tend to be more stable after AHSCT. Furthermore, these four candidate TCRBV/TCRBJ gene usages on CDR3 regions may act as therapeutic targets and biomarkers.